Why the study?
Does rAAV-asPLB gene transfer improve cardiac function and SERCA activity in a rat myocardial infarction model?
Population
Rat myocardial infarction (MI) model generated by ligating the left anterior descending coronary artery
Design
Preclinical
Follow-up
4 weeks
Key result
rAAV-asPLB gene transfer in rats with myocardial infarction effectively attenuated the depression of cardiac function, inhibited PLB expression, and enhanced SERCA activity.
Authors
Loading...
Preclinical support for SERCA restoration post-MI; leaves open safety, efficacy, and translation to human heart failure trials.
Does rAAV-asPLB gene transfer improve cardiac function and SERCA activity in a rat myocardial infarction model?
rAAV-asPLB gene transfer prevents the progression of heart failure in a rat model of myocardial infarction by restoring SERCA activity and inhibiting PLB expression.
Zhao et al. (2007) studied Myocardial infarction. rAAV-antisense phospholamban (asPLB) gene transfer vs. Control rats with MI was evaluated on Cardiac function (LVEF, LVSP, +/-dp/dtmax, LVEDP), SERCA activity, and PLB expression. rAAV-asPLB gene transfer in rats with myocardial infarction effectively attenuated the depression of cardiac function, inhibited PLB expression, and enhanced SERCA activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: